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Behavior is ultimately controlled by a combination of activity 
in a variety of neural circuits distributed across the brain. In 
several disease states, circuits that drive maladaptive behaviors 
are potentiated, whereas those that are more constructive 
become weakened. Juvenile brains are remarkably plastic and 
given an appropriate stimulus can often rebalance these cir-
cuits. However, after the closure of critical periods, adult brains 
become far less plastic making it necessary to artificially pro-
mote plasticity to repair damaged circuits. In principle, inter-
ventions that promote plasticity and enable the rebalancing of 
neural circuits can be used to treat a variety of brain diseases. 
Stress-related mood and anxiety disorders are particularly good 
examples of diseases resulting from circuit imbalances and thus 
are ideally suited to highlight plasticity-related strategies for 
improving brain health.
The prefrontal cortex (PFC) plays a critical role in the top-
down control of fear and reward and thus it is of central impor-
tance to the treatment of neuropsychiatric diseases such as 
posttraumatic stress disorder (PTSD) and depression. In fact, 
one of the hallmarks of depression is the retraction of dendrites 
and loss of dendritic spines and synapses in the PFC. These 
structural phenotypes are thought to underlie circuit-level 
changes leading to behaviors characteristic of the disease. The 
neurotrophic hypothesis of depression posits that loss of 
trophic support in areas of the brain such as the PFC and the 
hippocampus leads to atrophy of these brain regions, which 
ultimately disrupts critical mood-regulating circuits. Direct 
infusion of brain-derived neurotrophic factor (BDNF) into the 
PFC or hippocampus is known to produce antidepressant/
anxiolytic effects in rodents. Unfortunately, the proteinaceous 
nature of BDNF imparts poor pharmacokinetic properties and 
renders it completely ineffective as a systemically administered 
central nervous system (CNS) therapeutic. Therefore, small 
molecules capable of crossing the blood-brain barrier and acti-
vating plasticity mechanisms possess great medicinal value.
Compound-induced neural plasticity, sometimes referred to 
as iPlasticity, is a well-established phenomenon occurring after 
treatment with several classes of small molecules.1 However, 
most of these compounds act through slow, indirect processes 
typically relying on the regulation of neurotrophic factors and 
other proteins critical for plasticity. Traditional antidepressants, 
such as selective serotonin reuptake inhibitors, selective norepi-
nephrine reuptake inhibitors, and tricyclics, are some of the 
most efficacious plasticity-promoting compounds known. For 
example, traditional antidepressants increase the expression of 
BDNF and promote the growth of critical mood-regulating 
neurons in the PFC and hippocampus. In addition, fluoxetine 
can promote cortical remapping of ocular dominance columns 
and facilitate fear extinction learning.1 However, their effects 
on plasticity parallel their behavioral effects, which are quite 
slow and require chronic administration. Compounds that rap-
idly promote plasticity and produce beneficial, long-lasting 
behavioral changes represent an exciting advance over current 
plasticity-promoting medicines.
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The discovery that ketamine—a dissociative anesthetic—
produces fast-acting and relatively long-lasting antidepres-
sant effects has had a profound impact on psychiatry and 
represents one of the field’s most important findings in recent 
years. Ketamine promotes the growth of dendritic spines and 
the formation of synapses in the PFC within 24 hours of 
administration,2 a period of time that correlates with its anti-
depressant effects. Moreover, it has long-lasting effects, 
implicating positive neural adaptations in the circuits critical 
for regulating mood. Although extremely promising, keta-
mine is far from an ideal therapeutic as it has the potential for 
abuse. Therefore, a substantial amount of effort has been 
directed toward the identification of compounds that mimic 
the beneficial effects of ketamine. To classify compounds like 
ketamine capable of altering neural circuits by rapidly pro-
moting plasticity (Figure 1), and to distinguish them from 
other slow-acting molecules that induce plasticity, we have 
recently introduced the term “psychoplastogen,” from the 
Greek roots psych- (mind), -plast (molded), and -gen 
(producing).3
By definition, psychoplastogens are small molecules and 
thus plasticity-promoting proteins like BDNF do not fall 
into this category. To be classified as a psychoplastogen, a 
compound should produce a measurable change in plasticity 
(eg, changes in neurite growth, dendritic spine density, syn-
apse number, intrinsic excitability, etc.) within a short period 
of time (typically 24-72 hours) following a single adminis-
tration. Because their impact on neural plasticity enables 
subsequent stimuli to reshape neural circuits, they should 
produce relatively long-lasting changes in behavior that 
extend beyond the acute effects of the drug. In addition to 
ketamine, several other psychoplastogens have been identi-
fied, all of which produce fast-acting antidepressant effects 
in humans.4 These include the muscarinic receptor antago-
nist scopolamine,5 the NMDA receptor partial agonist 
GLYX-13 (ie, rapastinel),6 and 5-HT2A receptor agonists 
such as psychedelics (Table 1).
Recently, our group has demonstrated that psychedelic 
compounds such as lysergic acid diethylamide (LSD), N,N-
dimethyltryptamine (DMT), and 2,5-dimethoxy-4-iodoam-
phetamine promote dendritic branching and/or increase spine/
synapse number both in cultured cortical neurons and in vivo.3 
These results provide a potential explanation for the known 
ability of these compounds to produce long-lasting changes in 
personality and positively impact circuits relevant to the treat-
ment of mood, anxiety, and substance use disorders. Although 
our cellular studies have shown that a wide variety of psyche-
delic compounds produce psychoplastogenic effects similar to 
ketamine, our in vivo work thus far has primarily focused on 
the effects of DMT—the archetype for all tryptamine-con-
taining psychedelics.
Figure 1. Ketamine is the prototypical psychoplastogen. (A) Immature 
cultured cortical neurons (DIV6) treated with ketamine display increased 
dendritic branching compared to vehicle-treated neurons. (B) Mature 
cultured cortical neurons (DIV20) treated with ketamine display increased 
synapse formation relative to vehicle-treated neurons. VEH, vehicle; KET, 
ketamine; magenta, MAP2 staining; green, synapses determined by 
colocalization of pre- (VGLUT1) and postsynaptic (PSD-95) puncta.
Table 1. Examples of psychoplastogens with demonstrated in vivo 








Scopolamine Voleti et al5
DMT Ly et al3
DMT, N,N-dimethyltryptamine.
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Our initial efforts investigating the plasticity-promoting 
properties of psychedelics focused on DMT for a variety of 
reasons. First, the simple structure of DMT represents the 
minimal pharmacophore for all tryptamine-containing psych-
edelics as others such as LSD, ibogaine, psilocybin, and 
5-MeO-DMT can be considered either conformationally 
restricted or substituted analogues of DMT.7 Like ketamine,2 a 
single intraperitoneal injection of DMT increases dendritic 
spine density as well as the frequency and amplitude of sponta-
neous excitatory postsynaptic currents in the PFC of rats 
24 hours after administration. As the half-life of DMT in rats 
is on the order of 15 minutes, the compound is cleared from the 
body within 24 hours and thus these changes in neuronal struc-
ture and function must reflect plasticity and not simply the 
acute effects of the drug. Moreover, DMT produces behavioral 
effects in rodents that mirror those of ketamine such as pro-
moting fear extinction learning and reducing immobility in the 
forced swim test.8 In humans, a DMT-containing tisane 
known as ayahuasca has been shown to produce rapid and sus-
tained antidepressant effects.7
The use of a psychoplastogen to promote fear extinction 
learning is an excellent example of how small molecules can be 
used to rewire neural circuits. The PFC plays a critical role in 
encoding extinction memories and thus the administration of a 
psychoplastogenic compound shortly before extinction train-
ing can strengthen fear extinction memories more effectively 
than training alone. Like ketamine and DMT, the psychedelic 
3,4-methylenedioxymethamphetamine (MDMA) has been 
shown to promote fear extinction learning in rodents. 
Furthermore, MDMA has demonstrated great promise in the 
clinic for treating PTSD via a treatment paradigm that can 
best be described as pharmaceutical-enhanced psychotherapy.9 
The use of psychoplastogens to enhance fear extinction is gain-
ing traction and in principle, the same strategy could be used to 
extinguish drug-cue memories. Perhaps, this is why psyche-
delic compounds such as DMT, ibogaine, and LSD have shown 
promise for treating substance use disorders. The true thera-
peutic potential of psychoplastogens is not known, but the pos-
sibilities are incredibly exciting and include the treatment of 
stroke, brain trauma, and neurodegenerative diseases. In fact, 
slow-acting plasticity-promoting compounds such as fluoxe-
tine have already been used to promote functional recovery 
after brain insults.1
Mechanistically, psychoplastogens appear to induce changes 
in neuronal structure by activating the mammalian target of 
rapamycin (mTOR)—a key protein involved in cell growth, 
autophagy, and the production of proteins necessary for syn-
apse formation.10 Many psychoplastogens including ketamine, 
psychedelics, and scopolamine increase the secretion of gluta-
mate, which stimulates mTOR by activating AMPA receptors. 
However, many psychoplastogens alter perception or produce 
other undesired effects. A better mechanistic understanding of 
mTOR signaling in the brain could lead to the development of 
compounds with psychoplastogenic properties but better safety 
profiles. A number of companies and academic scientists are 
currently pursuing this strategy.
The most useful psychoplastogens will be the ones capable 
of promoting plasticity in a circuit-specific manner. While 
brain-penetrant small molecule TrkB agonists solved the 
pharmacokinetic problem of using BDNF as a therapeutic, 
they do not offer any selectivity as TrkB is widely distributed 
throughout the brain and the periphery. Promoting plasticity 
indiscriminately is not likely to be beneficial. For example, 
increased plasticity in the mesolimbic pathway could lead to 
addiction, whereas activation of TrkB on nociceptors could 
result in chronic pain. In terms of developing circuit-specific 
psychoplastogens, psychedelics are extremely attractive start-
ing points because they activate mTOR by stimulating 
5-HT2A receptors—receptors that are highly expressed on 
layer V pyramidal neurons of the cortex. This genetic locali-
zation ensures that psychoplastogenic effects are localized to 
cortical regions like the PFC and could possibly explain why 
psychedelic compounds are not generally considered to be 
addictive (ie, they do not promote plasticity in the mesolim-
bic pathway).
Although psychoplastogens offer many exciting possibilities 
for therapeutic interventions, it is important to consider the 
potential risks associated with promoting plasticity through 
the activation of mTOR. Excessive stimulation of mTOR has 
been associated with autism spectrum disorder and Alzheimer’s 
disease,10 and therefore, more research needs to be done to 
firmly establish the risks and benefits associated with using 
these compounds. Many psychoplastogens cause the release of 
glutamate leading to trophic effects; however, excessive gluta-
mate can result in excitotoxicity and neuronal atrophy. 
Therefore, the dose and frequency of administration will likely 
be critical to maximize efficacy while minimizing deleterious 
effects.
The advent of psychoplastogenic compounds has enabled us 
to move beyond simplistic therapeutic strategies aimed at con-
trolling monoamine levels toward the selective modulation of 
neural circuits—a fundamental shift in our approach to treating 
CNS disorders. Significant progress has been made in recent 
years and provides hope that modern research on ketamine, 
psychedelics, and other psychoplastogens will lead to safe and 
effective strategies for harnessing neural plasticity to treat mood 
and anxiety disorders such as depression and PTSD. As the 
number of psychoplastogenic compounds continues to grow, so 
do our chances of identifying the next generation of medicines 
for treating neuropsychiatric and neurodegenerative diseases. 
Regardless, it is clear that psychoplastogens can serve as power-
ful tools for understanding the basic biology of neural plasticity.
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